2024
Vilaprisan for the treatment of symptomatic endometriosis: results from a terminated phase 2b randomized controlled trial
Taylor H, Dong L, Haikonen J, Oppelt P, Tamussino K, Wenzl R, Faustmann T, Groettrup-Wolfers E, Ren X, Seitz C. Vilaprisan for the treatment of symptomatic endometriosis: results from a terminated phase 2b randomized controlled trial. F&S Reports 2024, 5: 189-196. PMID: 38983729, PMCID: PMC11228778, DOI: 10.1016/j.xfre.2024.03.002.Peer-Reviewed Original ResearchPelvic painSymptomatic endometriosisTreatment of symptomatic endometriosisEndometriosis-associated pelvic painBaseline to month 3Use of pain medicationAverage pain scoreMonths of treatmentPhase 2b randomized controlled trialAssess treatment effectsOutcome measures Primary outcomesPlacebo recipientsRandomized controlled trialsPain scoresMonth 3Pain medicationIncreased painVilaprisanPlaceboPrimary outcomeEndometriosisToxicity findingsIntervention participantsClinical relevanceBleeding intensity
2017
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
Taylor HS, Giudice LC, Lessey BA, Abrao MS, Kotarski J, Archer DF, Diamond MP, Surrey E, Johnson NP, Watts NB, Gallagher JC, Simon JA, Carr BR, Dmowski WP, Leyland N, Rowan JP, Duan WR, Ng J, Schwefel B, Thomas JW, Jain RI, Chwalisz K. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist. New England Journal Of Medicine 2017, 377: 28-40. PMID: 28525302, DOI: 10.1056/nejmoa1700089.Peer-Reviewed Original ResearchConceptsNonmenstrual pelvic painEndometriosis-associated painPelvic painClinical responsePercentage of womenPlacebo groupEnd pointPrimary efficacy end pointSevere endometriosis-associated painGonadotropin-releasing hormone antagonistOral GnRH antagonistRescue analgesic agentsEfficacy end pointPrimary end pointPhase 3 trialClinical response criteriaEstrogen-dependent conditionDaily electronic diaryBone mineral densityProportion of womenCorresponding percentagesEndometrial findingsEstrogen suppressionPain scoresHot flushes